Robert Harrington to Drug Approval
This is a "connection" page, showing publications Robert Harrington has written about Drug Approval.
Connection Strength
0.297
-
No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. Int J Cardiol. 2014 Sep; 176(1):300-2.
Score: 0.114
-
Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being. JAMA. 2012 Nov 07; 308(17):1743-4.
Score: 0.102
-
Premature release of data from clinical trials of ezetimibe. N Engl J Med. 2009 Aug 13; 361(7):712-7.
Score: 0.081